Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $35.01 USD
Change Today -0.03 / -0.09%
Volume 22.4M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 8:04 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by PFIZER INC (PFE) in the last 6 months

Announced 02/5/15
17.13B for Hospira Inc.
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) entered into a definitive merger agreement to acquire Hospira Inc. (NYSE:HSP) for $15.4 billion in cash on February 5, 2015. Under the terms, each outstanding share of Hospira will be converted into the right to receive $90 per share in cash. Each outstanding Hospira stock option, restricted stock unit, performance share award, performance restricted stock unit and restricted share will be cancelled and converted into the right to receive the consideration ...
Read More


PFE's price was unchanged after the transaction was announced on 02/5/15.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
NovaQuest Capital Management, L.L.C.
NovaQuest Healthcare Investment Fund, L.P.
T. Rowe Price Associates, Inc.
Financial Advisor
Morgan Stanley & Co. LLC
Legal Advisor
Skadden, Arps, Slate, Meagher & Flom, L.L.P.
 
Announced 01/5/15
Redvax GmbH
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) acquired a controlling stake in Redvax GmbH from Redbiotec AG on January 5, 2015.


PFE's price was unchanged after the transaction was announced on 01/5/15.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
Redbiotec AG
 
Announced 12/15/14
570.00M for Opko Health, Inc., Worldwide Licenses Of hGH-CTP
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) entered into an agreement to acquire worldwide licenses of hGH-CTP from Opko Health, Inc. (NYSE:OPK) for $570 million on December 13, 2014. Under the terms of the agreement, Opko Health will receive an upfront payment of $295 million and is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. The transaction is subject ...
Read More


PFE's price was unchanged after the transaction was announced on 12/15/14.
Investor / Buyer
Pfizer Inc.
Creditor / Lender
Opko Health, Inc.
 
Announced 12/8/14
iTeos Therapeutics SA
Private Placement

iTeos Therapeutics SA announced that it will receive equity funding from Pfizer Inc. on December 8, 2014.


PFE's price was unchanged after the transaction was announced on 12/8/14.
Investor / Buyer
Pfizer Inc.
 
Announced 10/23/14
11.00B for Pfizer Inc.
Buyback

Pfizer Inc. (NYSE:PFE) announces a share repurchase program. Under the program, the company will repurchase up to $11 billion worth of its shares. The plan will be utilized over time. The Board of Directors of Pfizer Inc. has authorized a buyback plan on October 23, 2014. On October 23, 2014, the company initiated a Market Repurchase. From October 23, 2014 to January 27, 2015, the company has repurchased 6,393,267 shares, representing 0.1% for $199.46 million. ...
Read More


PFE's price was unchanged after the transaction was announced on 10/23/14.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $35.01 USD -0.03

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $57.61 USD +0.73
Nestle SA SFr.74.00 CHF -1.95
Novartis AG SFr.97.70 CHF +0.50
Roche Holding AG SFr.273.10 CHF +2.90
Procter & Gamble Co/The $82.87 USD +0.34
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 24.8x
Price/Sales 4.4x
Price/Book 3.1x
Price/Cash Flow 16.3x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.